RGMB and breast carcinoma: In the presented study, we constructed and validated a 10‐lncRNA‐based signature (HAGLR, MIR210HG, RGMB‐AS1, TMEM161B‐AS1, CADM3‐AS1, LINC00293, LINC00910, LINC01187, PDZRN3‐AS1 and ZBED5‐AS1) to predict RFS for patients with breast cancer.